Association of Lipoprotein(a) With Puberty in IDDM

Couper, Jennifer; Bates, D. R.; Cocciolone, R.; Magarey, Anthea; Boulton, T. J. C.; Penfold, J. L.; Ryall, Rosemary L.

doi:10.2337/diacare.16.6.869

Cited by 31 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isoform analysis of these subjects is currently in progress to address these possibilities. Puberty has also been noted to affect Lp(a) levels [64]. At entry into this study, the average age of the subjects was the same in both groups (27 years of age) and each treatment group had a similar number of subjects less than 17 years of age.…”

Section: Discussionmentioning

confidence: 77%

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

Purnell¹,

Marcovina²,

Hokanson³

et al. 1995

Diabetes

View full text Add to dashboard Cite

Levels of lipoprotein (a) [Lp(a)], apolipoprotein (apo) B, and lipoprotein cholesterol distribution using density-gradient ultracentrifugation were measured as part of a cross-sectional study at the final follow-up examination (mean 6.2 years) in the Diabetes Control and Complications Trial. Compared with the subjects in the conventionally treated group (n = 680), those subjects receiving intensive diabetes therapy (n = 667) had a lower level of Lp(a) (Caucasian subjects only, median 10.7 vs. 12.5 mg/dl, respectively; P = 0.03), lower apo B (mean 83 vs. 86 mg/dl, respectively; P = 0.01), and a more favorable distribution of cholesterol in the lipoprotein fractions as measured by density-gradient ultracentrifugation with less cholesterol in the very-low-density lipoprotein and the dense low-density lipoprotein fractions and greater cholesterol content of the more buoyant lowdensity lipoprotein. Compared with a nondiabetic Caucasian control group (n = 2,158), Lp(a) levels were not different in the intensive treatment group (median 9.6 vs. 10.7 mg/dl, respectively; NS) and higher in the conventional treatment group (9.6 vs. 12.5 mg/dl, respectively; P less than 0.01). No effect of renal dysfunction as measured by increasing albuminuria or reduced creatinine clearance on Lp(a) levels could be demonstrated in the diabetic subjects. Prospective follow-up of these subjects will determine whether these favorable lipoprotein differences in the intensive treatment group persist and whether they influence the onset of atherosclerosis in insulin-dependent diabetes. Lp(a) is formed by a molecule of a carbohydrate-rich protein named apo(a) linked by a single disulfide bond to the apo B of an LDL-like lipoprotein. Like LDL, Lp(a) is thought to be atherogeic. Because of the structural homology of apo(a) to plasminogen, it is also thought to have thrombogenic properties. This potential combination of proatherogenic and prothrombotic properties has led to a surge of research into the role of Lp(a) in atherosclerosis. KeywordsIn several case-controlled and prospective studies consisting primarily of white men with at least one preexisting cardiac risk factor, such as a family history of heart disease or an elevated LDL cholesterol level, an increased Lp(a) level has been shown to be an independent risk factor for CAD [5,10,11].Because up to 91 percent of the variability in plasma Lp(a) levels between individuals has been attributed to the apo(a) isoform [5,12], the contribution of age, sex, diet, and exercise to Lp(a) levels is thought to be small. Lp(a) levels have been shown to be higher in familial hypercholesterolemia [13], chronic renal failure [14][15][16][17][18][19], and nephrotic syndrome [20][21][22][23][24][25], and lower levels have been reported in cirrhosis [26]. How Lp(a) levels might be affected by IDDM and its complications and whether Lp(a) contributes to CAD [27,28] in this population remain controversial. Some investigators found elevated Lp(a) levels in subjects with IDDM compared with normoglycemic co...

show abstract

Section: Discussionmentioning

confidence: 77%

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

Purnell¹,

Marcovina²,

Hokanson³

et al. 1995

Diabetes

View full text Add to dashboard Cite

show abstract

“…LDL cholesterol was calculated using the Friedewald equation (21). Lipoprotein (a) [Lp(a)] was measured using end point nephelometry (Hyland laser nephelometry PDQ) and addition of specific monoclonal antibodies, as previously described (22). Statistics.…”

Section: Diabetes Vol 51 July 2002mentioning

confidence: 99%

Endothelial Dysfunction Relates to Folate Status in Children and Adolescents With Type 1 Diabetes

Wiltshire¹,

Gent

Hirte

et al. 2002

Diabetes

View full text Add to dashboard Cite

Endothelial dysfunction occurs early in the development of vascular disease in diabetes. Total plasma homocyst(e)ine (tHcy) is associated with endothelial dysfunction. We therefore aimed to assess endothelial function in children with type 1 diabetes in relation to tHcy and its determinants. Endothelial function was assessed in 36 children with type 1 diabetes aged 13.7 ؎ 2.2 years and 20 age-and sex-matched control subjects using ultrasound assessment of flow-mediated dilatation (FMD) and glyceryl trinitrate (

show abstract

“…A cross-sectional survey of young IDDM patients without microalbuminuria reported an increase of lipoprotein(a) during and after puberty (Tanner stages 2-5) [56]. The increase of growth hormone secretion that occurs with puberty may play a role in this change, because growth hormone replacement therapy in adults with hypopituitarism has been shown to increase levels of lipoprotein(a) [57].…”

Section: Lipoprotein(a) Puberty and Exercisementioning

confidence: 99%